AI Article Synopsis
- The study investigates the effectiveness of aerobic exercise as a potential treatment for individuals dependent on methamphetamine (MA), a condition with limited pharmacological options.
- It involves randomizing 150 participants at a residential treatment facility to either an exercise program or a health education group, with recruitment starting in March 2010 and exceeding initial goals.
- The goal is to assess whether an 8-week exercise regimen can reduce relapse rates and improve overall health during a 12-week follow-up post-treatment.
Article Abstract
Background: Effective pharmacotherapies to treat methamphetamine (MA) dependence have not been identified, and behavioral therapies are marginally effective. Based on behavioral studies demonstrating the potential efficacy of aerobic exercise for improving depressive symptoms, anxiety, cognitive deficits, and substance use outcomes, the study described here is examining exercise as a potential treatment for MA-dependent individuals.
Methods: This study is randomizing 150 participants with MA dependence at a residential treatment facility for addictive disorders to receive either a thrice-weekly structured aerobic and resistance exercise intervention or a health education condition. Recruitment commenced in March, 2010. Enrollment and follow-up phases are ongoing, and recruitment is exceeding targeted enrollment rates.
Conclusions: Seeking evidence for a possibly effective adjunct to traditional behavioral approaches for treatment of MA dependence, this study is assessing the ability of an 8-week aerobic and resistance exercise protocol to reduce relapse to MA use during a 12-week follow-up period after discharge from residential-based treatment. The study also is evaluating improvements in health and functional outcomes during and after the protocol. This paper describes the design and methods of the study.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4431553 | PMC |
| http://dx.doi.org/10.1016/j.cct.2013.11.010 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Mesolimbic dopamine neurons drive infradian rhythms in sleep-wake and heightened activity state.
Sci Adv
January 2025
Douglas Mental Health University Institute, McGill University, Montreal, QC H4H 1R3, Canada.
Infradian mood and sleep-wake rhythms with periods of 48 hours and beyond have been observed in patients with bipolar disorder (BD), which even persist in the absence of exogenous timing cues, indicating an endogenous origin. Here, we show that mice exposed to methamphetamine in drinking water develop infradian locomotor rhythms with periods of 48 hours and beyond which extend to sleep length and manic state-associated behaviors in support of a model for cycling in BD. The cycling capacity is abrogated upon genetic disruption of dopamine (DA) production in DA neurons of the ventral tegmental area (VTA) or ablation of nucleus accumbens projecting DA neurons.
View Article and Find Full Text PDFDisrupting heroin-associated memory reconsolidation through actin polymerization inhibition in the nucleus accumbens core.
Int J Neuropsychopharmacol
December 2024
National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China.
Background: Understanding drug addiction as a disorder of maladaptive learning, where drug-associated or environmental cues trigger drug cravings and seeking, is crucial for developing effective treatments. Actin polymerization, a biochemical process, plays a crucial role in drug-related memory formation, particularly evident in conditioned place preference paradigms involving drugs like morphine and methamphetamine. However, the role of actin polymerization in the reconsolidation of heroin-associated memories remains understudied.
View Article and Find Full Text PDFPsilocybin-assisted psychotherapy for methamphetamine dependence: a case report involving daily methamphetamine use.
Front Psychiatry
December 2024
New York University (NYU) Postdoctoral Program in Psychotherapy and Psychoanalysis, New York University (NYU) Grossman School of Medicine, New York, NY, United States.
Methamphetamine (MA) dependence leads to severe physical and psychological issues. Current treatments, including psychosocial therapies and residential rehabilitation, face limitations such as high relapse rates, cost, and accessibility issues. As a result, there is an urgent need for novel approaches to treat MA dependence that are effective, affordable, and accessible to patients.
View Article and Find Full Text PDFLisdexamfetamine in the treatment of methamphetamine dependence: A randomised, placebo-controlled trial.
Addiction
December 2024
Drug and Alcohol Clinical Research and Improvement Network, NSW Health, Sydney, Australia.
Aims: This study tested the efficacy and safety of a 12-week course of lisdexamfetamine in reducing methamphetamine use, an outcome which is associated with improvements in health and wellbeing, in people dependent on methamphetamine.
Design, Setting And Participants: This study was a randomised double-blind placebo-controlled trial conducted in six specialist outpatient clinics in Adelaide, Melbourne, Newcastle and Sydney, Australia (2018-2021). Participants were164 adults with methamphetamine dependence, reporting at least 14 use days out of the previous 28 days (62% male, 38% female, < 1% other; mean age 39 years).
Interactions of VMAT2 with CDCrel-1 and Parkin in Methamphetamine Neurotoxicity.
Int J Mol Sci
December 2024
Department of Pharmaceutical Sciences, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, 259 Mack Ave., Detroit, MI 48201, USA.
In recent years, methamphetamine (METH) misuse in the US has been rapidly increasing, and there is no FDA-approved pharmacotherapy for METH use disorder (MUD). In addition to being dependent on the drug, people with MUD develop a variety of neurological problems related to the toxicity of this drug. A variety of molecular mechanisms underlying METH neurotoxicity has been identified, including the dysfunction of the neuroprotective protein parkin.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!